• Receipt of orders from Carl Zeiss Meditec AG (CZM) for approx. A$350k
• Continued diversification of OptiScan Revenue Streams with receipts of A$570k from the balance of the payments for the 2 FIVE2 (ViewnVivo) sales to China based customers, the BioMedTech Horizons Program grant and from CZM in the December 2020 quarter.
Carl Zeiss Meditec AG Orders
OptiScan Imaging Limited (ASX: OIL) (‘the Company’ or ‘OptiScan’) is pleased to advise that it has received orders from Carl Zeiss Meditec AG pursuant to its Co-operation Agreement for approximately A$350k.
OptiScan’s CEO and Executive Chairman Darren Lurie, said:
“The orders from CZM represent the continuation of CZM’s commercial rollout of the CONVIVO® developed as part of the co-operation agreement between CZM and OptiScan.
We are also very pleased that OptiScan continues to diversify its revenue streams and cash flows. Receipts in the December 2020 quarter included $570k from the final payments for the 2 (two) FIVE2 (ViewnVivo) systems sold to China based customers, the BioMedTech Horizons Program grant to support the University of Melbourne’s Melbourne Dental School trial and payments from CZM. ”
About Optiscan Imaging Limited (ASX:OIL)
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Optiscan has a collaboration with leading European medical technology company, Carl Zeiss Meditec AG and our technology is a critical part of the ZEISS CONVIVO™, that has brought OptiScan’s technology into the field of Neurosurgery. FDA 510(k) clearance and CE Mark have been obtained for the ZEISS CONVIVO™.